Business Presentation Internacional

8/13/2019 Business Presentation Internacional

http://slidepdf.com/reader/full/business-presentation-internacional 1/40

LAFRANCOL

Quality and Innovative PharmaceuticalProducts Since 1911



Company Overview

Founded in 1911

Successfully distributed French pharmaceutical

products in Latin America - bulk imports, packaging

and distribution.

In 1945, Lafrancol opens its first plant becoming the

first manufacturer of pharmaceuticals in Colombia

Continuous modernization has resulted in one of the

most modern plants in Latin America.

Today, Lafrancol is the #1 Pharmaceutical

Company in Colombia



MARKET POSITION



A commitment to providing quality products has established

Lafrancol as a leader in its markets:

# 1 Pharmaceutical company in sales (including multi-nationals)1

# 3 Pharmaceutical company in prescriptions2

# 1 Pharmaceutical company in new products for the last 10 years1

# 2 Pharmaceutical Company in the hormonal market1

Only Pharmaceutical Company with an Anti_TNF Biocompetitor

product worldwide (except China)

Source: 1. IMS MAT_Dec_2011 2. Close_Up MAT_Dec_2011

Lafrancol: Premiere Enterprise

DATA

DATA

DATA

DATA



Lafrancol ranks first in sales volume (including multi-nationals), in the ethical market without

milk top ten companies, with 11.92% growth, and posted the largest market gain in the

industry.Source: IMS MAT_Dec_2011

Snapshot - Leading Manufacturers

0

20,000,000,000

40,000,000,000

60,000,000,000

80,000,000,000

100,000,000,000

120,000,000,000

140,000,000,000

160,000,000,000

180,000,000,000

200,000,000,000

L

a f r a n c o l

B a y e r P h a r m a c e u t i c

P f i z e r

M s d

S a n o f i

A v e n t i s

G e n f a r

M

c k e s s o n

P r o c a p s

G l a x o s m

i t h k l i n e

B o e

h r

i n g e r

I n g



Rank 17

Rank 13

Rank 7

Rank 3

Rank 1

Rank 1

Ranking in IMS and Sales growth

20%3%

17%

29%

26%

26%11%

41%

38%

22%

3%5%

19%

Source: IMS Top Manufacturers 1999-2011 Ethical Market Without Milk / Internal Sales Data

Rank 1

Long-term – Aggressive Growth to the Top



Top Ten Laboratories in the Total Market– Market Share %

Source: IMS December 2011

Lafrancol – Overtaking the Multinationals

2,00%

3,00%

4,00%

5,00%

6,00%

7,00%

M T H e n e / 1 0

M T H f e b / 1 0

M T H m a r / 1 0

M T H a b r / 1 0

M T H m a y / 1 0

M T H j u n / 1 0

M T H j u l / 1 0

M T H a g o / 1 0

M T H s e p / 1 0

M T H o c t / 1 0

M T H n o v / 1 0

M T H d i c / 1 0

M T H e n e / 1 1

M T H f e b / 1 1

M T H m a r / 1 1

M T H a b r / 1 1

M T H m a y / 1 1

M T H j u n / 1 1

M T H j u l / 1 1

M T H a g o / 1 1

M T H s e p / 1 1

M T H o c t / 1 1

M T H n o v / 1 1

M T H d i c / 1 1

Lafrancol - (232) Bayer Pharmaceutic - (70) Nestle - (17) Glaxosmithkline - (88)

Msd - (91) Pfizer - (83) Abbott - (60) Mckesson - (185)

Sanofi Aventis - (86) Genfar - (150)







THE LAFRANCOL

ADVANTAGE



Experienced workforce of 2,500+ employees 40% in Research and Manufacturing.

60% Sales and Marketing.

Strongest & most aggressive sales force in Colombia.

Largest medical sales force Top selling sales force for last 10 years.

Proven team as demonstrated by the most successful new product launches in the

industry over the last 10 years.

Aggressive operation with 45,000+ sales visits per month to physicians.

Rapid market penetration Via successful marketing & distribution strategies.

Resulting in highest market share gains in the industry.

Advantage:

Sales & Marketing



Physicians Continued Medical Education and Educational University Grants

Distribution Excellent Relationships with Wholesalers, Distributors, Private & Government Entities and Pharmacies.

Patients Through“Health Centers” and Call Centers, patients are provided support on product information, adherence to

therapies and medicines, how to change their nutritional habits and adhere to new habits to achieve a better quality oflife.

Patient Care Programs (Cuidarte) : Focuses on assisting and educating patients using biotech

and specialty care products by assisting patients with:

At-home drug application.

Patient and nurse training.

Biosecurity training.

Pharmacovigilance program & pharmaceutical care.

Follow-up evaluations on adherence and patient satisfaction .

Advantage:

Pervasive Relationships



Advantage:

Specialized Studies

The only national pharmaceutical company with more than

30 studies in specialized areas:



Modern plants equipped with the latest technology and providing flexibleproduction capabilities.

o Cali, Colombia: 23,000 m2 modern, state-of-the-art manufacturing facility.

o Colombian Duty-Free Zone: 2,100 m2 manufacturing facility.

Leader in social and environmental responsibility.

Each plant operates under the most stringent quality control, as defined byinternational standards, including:

o

GMP (Good Manufacturing Practices for Pharmaceuticals).o ISO (International Organization for Standardization) 9001.

o ISO (International Organization for Standardization) 28000.

o PIC (Pharmaceutical Inspection Convention).

o FDA plant compliance is currently in process.

Advantage:

Manufacturing



PRODUCTS



Product Types

Injectables - Hormones

Tablets

Capsules

Granulates Ointments

Creams

Gels

Syrups

Sachets

Powders

Sterile Liquids



Product Lines

Branded Rx

Generics

Specialty Care: High Cost and Institutional(Private & Government)

Biotech, Oncology, & HIV

OTC

Pharmaceuticals, Nutraceuticals andFunctional Foods



Therapeutic Lines

NOTE: To view products click on image



SALES OPERATIONS



Offices in Colombia

Bogotá Corporate

Medical Research

Marketing

Sales

Cali

Operations & Production

Financial

Regional Offices

Sales & Marketing Sales Force for Physicians

Health Club for Patients

Health Nutritional Institute





International Operations

Exports Performance

0

2.000.000

4.000.000

6.000.000

8.000.000

10.000.000

12.000.000

14.000.000

2007 2008 2009 2010 2011

Values & Growth

54%26%

54%

19%

56%

Source: Internal Data on File

USD





Therapeutic Lines



Therapeutic Lines



Therapeutic Lines



Therapeutic Lines



Therapeutic Lines



Therapeutic Lines



Therapeutic Lines



Therapeutic Lines



Therapeutic Lines



Lafrancol : Market Leader

Total MarketSales - Total Market

(General Configuration: IMS Struct / Active to: Historical / Cut Off: 10 Rows / Filters: No / )

Local Currency Local Currency Units

MAT dic/11 MAT dic/11 MTH dic/11 MAT dic/11 MTH dic/11

Total Selected Accumulated 3,992,954,038,423 365,775,183,353 328,289,091 29,893,534

1 Lafrancol - (243) 6.1% 244,691,755,462 21,325,479,938 24,520,108 2,007,286

2 Glaxosmithkline - (104) 11.1% 198,981,237,527 15,791,894,250 15,403,599 1,230,079

3 Pfizer - (93) 15.5% 175,138,272,715 15,315,026,876 5,152,909 431,994

4 Bayer Pharmaceutic - (73) 19.7% 169,561,079,791 18,842,510,839 7,642,966 1,013,321

5 Msd - (99) 23.9% 164,220,469,542 15,342,459,853 7,369,966 756,727

6 Nestle - (17) 27.8% 157,160,826,861 15,900,248,974 9,893,256 986,461

7 Abbott - (65) 31.6% 151,883,692,303 14,292,667,004 9,280,479 881,599

8 Sanofi Aventis - (87) 35.3% 149,788,666,968 12,831,109,940 5,581,281 490,891

9 Mckesson - (190) 38.7% 132,223,018,131 13,226,631,898 22,231,407 2,206,092

10 Boehringer Ing - (54) 41.6% 117,870,674,910 10,250,202,520 8,213,799 689,827

Others (330) 100.0% 2,331,434,344,213 212,656,951,261 212,999,321 19,199,257

Source: IMS MAT_Dec_11



Lafrancol : Hormonal Market

Segment AnalysisSales - G

(General Configuration: IM S Struct / Active to: Historic al / CutOff: 10 Rows / Filters: No / )

Local Currency Local Currency Units

MTH dic/11 MAT dic/11 MTH dic/11 MAT dic/11 MTH dic/11

Total Se lected Accumulated 398,709,673,120 39,294,770,911 31,011,598 3,008,393

1 Bayer Pharmaceutic - (30) 30.6% 92,434,124,903 12,038,935,449 4,761,064 732,663

2 Lafrancol - (31) 46.8% 70,215,787,546 6,355,843,398 6,651,239 591,501

3 Pfi zer - (14) 51.2% 20,145,343,167 1,730,375,162 1,000,892 78,084

4 Sanofi Aventis - (8) 55.6% 21,692,234,350 1,706,986,815 1,107,910 92,839

5 Boehringer Ing - (5) 59.8% 19,803,995,130 1,674,235,513 885,946 68,554

6 Gynopharm - (16) 63.7% 15,667,995,808 1,515,141,064 794,234 65,787

7 Profamilia - (9) 67.3% 17,270,354,487 1,405,539,744 1,483,500 120,582

8 Lilly - (2) 70.1% 11,693,206,576 1,133,078,350 192,844 18,064

9 Tecnofarma - (8) 72.1% 8,812,067,156 784,337,737 135,659 12,084

10 Bayer Consume Care - (2) 74.1% 8,819,688,802 781,050,720 565,746 48,386

Others (95) 100.0% 112,154,875,195 10,169,246,959 13,432,564 1,179,849

Source: IMS MAT_Dec_11



Lafrancol : New Products

Source: IMS Colombia Dec_11





Advantage:Special Studies

APLAR, Taiwan 2.011

EULAR. Londres 2.011

American College of Rheumathology, Atlanta 2.010






Advantage:

Special Studies




Date post:	04-Jun-2018
Category:	Documents
Upload:	vanessa-gomez-londono
View:	216 times
Download:	0 times

Business Presentation Internacional

Documents